Transcatheter Aortic Valve Implantation Without Predilation (SIMPLIFy TAVI)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to demonstrate that the avoidance of balloon valvuloplasty for predilation of the native aortic valve is associated with a reduction of the composite primary endpoint in TAVI patients with severely impaired left-ventricular ejection fraction (LVEF ≤35%).
| Condition | Intervention |
|---|---|
|
Aortic Stenosis Left Ventricular Function Systolic Dysfunction High-risk Patients Transcatheter Aortic Valve Implantation |
Procedure: TAVI without BAV Procedure: TAVI standard procedure |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Use of the Self-Expanding Medtronic CoreValve Prosthesis Without Predilation in Patients With Severely IMPaired Left-VentrIcular Ejection Fraction for TAVI Trial - The SIMPLIFy TAVI Trial |
- Primary composite efficacy endpoint [ Time Frame: 30 days after TAVI ] [ Designated as safety issue: Yes ]Occurrence of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantation at 30 days after TAVI.
- Cardiovascular & all-cause mortality [ Time Frame: 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Major/minor stroke [ Time Frame: 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Myocardial infarction [ Time Frame: 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- conduction disturbances and pacemaker implantation rate [ Time Frame: 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Acute kidney injury [ Time Frame: 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Rate of postdilation [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Transvalvular mean gradient as assessed by echocardiography [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Re-hospitalization for symptoms of cardiac/valve-related decompensation [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Severity of periprosthetic aortic regurgitation (AR) as assessed by echocardiography, angiography, and hemodynamic measurements (AR index) [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Life-threatening/major/minor bleeding [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Vascular access complications [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
- Repeat procedure for valve-related dysfunction (surgical or interventional therapy) [ Time Frame: 30 days, 6 months, 12 months after TAVI ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 110 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: TAVI without predilation |
Procedure: TAVI without BAV
Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
|
| Active Comparator: Standard TAVI procedure |
Procedure: TAVI standard procedure
TAVI standard procedure including BAV before valve deployment
|
Detailed Description:
Transcatheter aortic valve implantation (TAVI) has evolved as an alternative to surgical aortic valve replacement (SAVR) with now more than 50,000 implantations in patients with symptomatic severe aortic stenosis, who were considered to be at very high or prohibitive operative risk. Before deployment of transcatheter heart valves (THV), current medical practice requires right-ventricular rapid burst pacing (>180 bpm) with induction of a functional cardiac arrest for up to 30 seconds for balloon aortic valvuloplasty (BAV). This step is thought to be necessary to predilate the native aortic valve and to facilitate an accurate positioning of the THV. However, BAV has been shown to have numerous detrimental effects: i) the functional cardiac arrest induced by rapid pacing for BAV leads to transient coronary, cerebral, and renal ischemia. ii) In patients with impaired left ventricular ejection fraction, prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS), which are both associated with a high peri-procedural mortality. iii) BAV has been identified as a major source of embolization of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke. iv) the local trauma in the left-ventricular outflow tract caused by BAV contributes to conduction disturbances with the need for permanent pacemaker implantation after TAVI.
A non-randomized pilot study by Grube et al. (JACC Interventions 2011) has recently shown that TAVI without BAV is feasible and safe, since self-expanding THV are able to "dilate" the stenosed aortic valve through the radial forces of the self-expanding nitinol frame, in which the prosthesis is mounted. According to the mentioned study, omitting BAV allows the delivery of the THV in a controlled fashion without hemodynamic compromise of the patient.
Patients with LVEF≤35% will be randomized (like the flip of a coin) to TAVI without BAV (experimental group) or TAVI with BAV for predilation (control group).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- LVEF ≤35%
- Aortic valve stenosis with an aortic valve area <1 cm2 (<0,6 cm3/m2)
- Males or females at least 18 years of age
- Logistic EuroSCORE ≥15% and age ≥75 years or if age <75 years: logistic EuroSCORE ≥20% and/or a significant contraindication for open heart surgery (e.g., porcelain aorta or severe COPD)
- Signed informed consent
Exclusion Criteria:
- Patients with a device regulating the heart rhythm by pacing (e.g. pacemaker, resynchronization device, implanted defibrillator)
- Patients with a pre-existing class I or class II indication for new pacemaker implantation according to the 2007 ESC guidelines
- Lack of written informed consent, severe mental disorder, drug/alcohol addiction
- Life expectancy < 1 year
- Hypersensitivity or contraindication to acetyl salicyl acid, heparin, ticlopidine, clopidogrel, nitinol or sensitivity to contrast media that cannot be adequately premedicated
- Recent myocardial infarction (STEMI within the last 3 months)
- Left ventricular or atrial thrombus by echocardiography
- Uncontrolled atrial fibrillation
- Mitral or tricuspidal valvular insufficiency (> grade II)
- Previous aortic valve replacement with mechanical valve
- Evolutive or recent cerebrovascular event (within the last 3 months)
- Vascular conditions that make insertion and endovascular access to the aortic valve impossible
- Symptomatic carotid or vertebral arterial narrowing (>70%) disease
- Abdominal or thoracic aortic aneurysm in the path of the delivery system
- Bleeding diathesis or coagulopathy or patient refusing blood transfusion
- Active gastritis or peptic ulcer disease
- Severely impaired renal function, GFR < 30 ml/min
- Participation in another drug or device study that would jeopardize the appropriate analysis of end-points of this study.
- High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
- Pregnancy
Contacts and Locations| Contact: Jan-Malte Sinning, MD | +49-228-287-15507 | jan-malte.sinning@ukb.uni-bonn.de |
| Germany | |
| Department of Medicine II - Cardiology, University Hospital Bonn | Recruiting |
| Bonn, Germany, 53105 | |
| Contact: Jan-Malte Sinning, MD | |
| Principal Investigator: Georg Nickenig, MD | |
| Principal Investigator: Jan-Malte Sinning, MD | |
| Department of Cardiology, University Hospital Düsseldorf | Not yet recruiting |
| Düsseldorf, Germany, 40225 | |
| Contact: Malte Kelm, MD | |
| Principal Investigator: Malte Kelm, MD | |
| West German Heart Center, University Hospital Essen | Not yet recruiting |
| Essen, Germany, 45122 | |
| Contact: Raimund Erbel, MD | |
| Principal Investigator: Raimund Erbel, MD | |
| Principal Investigator: Philipp Kahlert, MD | |
| Department of Medicine III - Cardiology, University Hospital Heidelberg | Not yet recruiting |
| Heidelberg, Germany, 69120 | |
| Contact: Hugo A Katus, MD | |
| Principal Investigator: Hugo A Katus, MD | |
| Principal Investigator: Raffi Bekeredjian, MD | |
| Department of Cardiology, Hospital Barmherzige Brüder Trier | Not yet recruiting |
| Trier, Germany, 54292 | |
| Contact: Karl Eugen Hauptmann, MD | |
| Principal Investigator: Karl Eugen Hauptmann, MD | |
| Department of Medicine III - Cardiology, University Hospital Tübingen | Not yet recruiting |
| Tübingen, Germany, 72076 | |
| Contact: Meinrad Gawaz, MD | |
| Principal Investigator: Meinrad Gawaz, MD | |
| Principal Investigator: | Georg Nickenig, MD | Department of Medicine II, University Hospital Bonn |
| Study Director: | Jan-Malte Sinning, MD | Department of Medicine II, University Hospital Bonn |
More Information
Publications:
| Responsible Party: | Georg Nickenig, Director, Department of Medicine II, University Hospital, Bonn |
| ClinicalTrials.gov Identifier: | NCT01539746 History of Changes |
| Other Study ID Numbers: | SIMPLIFy TAVI Trial |
| Study First Received: | February 21, 2012 |
| Last Updated: | January 30, 2013 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by University Hospital, Bonn:
|
Aortic stenosis Transcatheter aortic valve implantation TAVI Predilation |
Balloon valvuloplasty BAV CoreValve |
Additional relevant MeSH terms:
|
Aortic Valve Stenosis Constriction, Pathologic Heart Valve Diseases Heart Diseases |
Cardiovascular Diseases Ventricular Outflow Obstruction Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 23, 2013